On Wednesday, TD Cowen reaffirmed its Buy rating on shares of Hims & Hers Health, Inc. (NYSE: HIMS), maintaining a price target of $28.00. The firm's commentary focused on recent legal developments involving the FDA and the Outsourcing Facilities Association (OFA) concerning the drug tirzepatide. A Joint Status report proposed by the FDA is scheduled for November 21, 2024, which may clarify the drug's availability status.
The analyst from TD Cowen highlighted the significance of the upcoming report and its potential impact on the market. If tirzepatide is removed from the shortage list following the resolution of the legal case, it is anticipated that semaglutide, another medication in the same category, could follow suit.
The legal action taken by the OFA against the FDA has been a point of focus for industry observers. The association is challenging the FDA's decision to remove tirzepatide from the shortage list. The outcome of this case is expected to have implications for the availability of semaglutide, a drug used for similar therapeutic purposes.
The discussion around drug shortages and legal disputes with the FDA is particularly relevant for companies like Hims & Hers, which operate in the health and wellness space. The resolution of such cases can have direct effects on their product offerings and market dynamics.
TD Cowen's reiteration of the Buy rating and price target for Hims & Hers comes at a time when the healthcare industry is closely monitoring regulatory developments. The firm's analysis suggests that the resolution of the tirzepatide case could be a positive development for Hims & Hers, provided that the outcome is favorable and semaglutide experiences a similar regulatory trajectory.
In other recent news, Hims & Hers Health, Inc. has been the topic of several analyst reports. BofA Securities downgraded the company's rating from Buy to Underperform due to Amazon (NASDAQ:AMZN)'s entry into key markets for Hims & Hers, potentially affecting their pricing and customer acquisition. Despite this, the company reported a 77% year-over-year increase in third-quarter sales, surpassing $400 million, and an adjusted EBITDA over $50 million.
Piper Sandler raised Hims & Hers' price target from $18 to $21, maintaining a Neutral stance, while Needham raised the price target to $28, maintaining a Buy rating. TD Cowen also reiterated a Buy rating with a $25 price target, and Citi raised its price target to $24 from $20, maintaining a Neutral rating.
These developments follow Hims & Hers' announcement of plans to diversify its product offerings, including the launch of liraglutide, the first generic GLP-1, in 2025. The company is also forecasting Q4 2024 revenue between $465 million and $470 million, marking an 89% to 91% year-over-year increase. The full-year revenue is projected to be between $1.46 billion and $1.465 billion, reflecting a 67% to 68% increase.
InvestingPro Insights
Hims & Hers Health, Inc. (NYSE: HIMS) has been experiencing significant growth, as reflected in the latest InvestingPro data. The company's revenue growth of 56.7% over the last twelve months and an impressive 77.13% growth in the most recent quarter underscore its strong market position. This robust growth aligns with TD Cowen's bullish stance on the stock.
InvestingPro Tips highlight that net income is expected to grow this year, and four analysts have revised their earnings upwards for the upcoming period. These positive indicators support the company's potential to capitalize on favorable regulatory outcomes, such as the possible resolution of the tirzepatide case mentioned in the article.
The company's financial health appears solid, with liquid assets exceeding short-term obligations and a moderate level of debt. This financial stability could provide Hims & Hers with the flexibility to adapt to changing market conditions and regulatory landscapes in the healthcare industry.
Investors should note that HIMS is trading at a high P/E ratio of 49.32, which may reflect market expectations of continued growth. The stock has also shown strong performance, with a 204.01% return over the past year, indicating investor confidence in the company's prospects.
For those interested in a deeper analysis, InvestingPro offers 13 additional tips for HIMS, providing a more comprehensive view of the company's potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.